Summary by Futu AI
On February 15, 2024, T2 Biosystems, a medical diagnostic company, reported its financial results for the fiscal quarter and full year ended December 31, 2023. The announcement was made through a press release and during a conference call, the transcript of which was furnished as Exhibit 99.1 in a Form 8-K filed with the SEC. The company, headquartered in Lexington, Massachusetts, and incorporated in Delaware, is listed on the Nasdaq Capital Market under the trading symbol TTOO. T2 Biosystems reported full year total revenue of $7.3 million, with product revenue of $6.7 million, and a record sales of its T2Bacteria Panel in the U.S. market. The company added 26 T2Dx Instruments to its installed base, which is nearing 200 globally. For the fourth quarter of 2023, sepsis and related product revenue was $1.7 million...Show More